Ernexa Therapeutics Provides Update on Operational Excellence and Performance

The company’s operating loss declined by 51% year-over-year, reflecting a laser focus on relentless execution and significant progress in expense reductionCAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided an update on its operational excellence and performance for the first half of 2025. The company reported its financial results in its Quarterly Report on F ...